Jonathan Campbell, PhD, Associate Professor of Medicine at Duke University, will discuss how glucagon receptor agonism adds to the effect of GIP and GLP-1 receptor agonism
Post-marketing surveillance study in Central America
Diabetes Care 39(2):231241 Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D (2020) Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5
Unlike other growth hormone secretagogues such as GHRP-6 or hexarelin, ipamorelin demonstrates a narrow selectivity profile, stimulating GH release in a dose-dependent manner without appreciably altering cortisol, ACTH, or prolactin levels